Bausch + Lomb Provides Update on Potential Sale and Future Plans

Bausch + Lomb has announced that it has no immediate plans to go private, following an evaluation of a potential sale. This update comes after a request from the Canadian Investment Regulatory Organization (CIRO) in December 2024 to explore the possibility of a sale.

No Transaction Following Buyer Engagement

In a recent statement, Bausch + Lomb confirmed that while going private with a third-party buyer was one of several options considered to complete a full separation from Bausch Health Companies Inc., the process has now concluded without a transaction.

"Full separation remains the goal," the company stated. "Bausch + Lomb continues to operate as its own entity, executing its strategies and business plan." The company also reiterated its financial strength, having raised its 2024 revenue guidance on October 30 and scheduled its fourth-quarter and full-year 2024 earnings report for February 19, along with its 2025 fiscal year guidance.

CIRO Request and Market Considerations

The potential sale of Bausch + Lomb would have resulted in a complete separation from Bausch Health Companies Inc. However, the company noted that it does not typically comment on deal negotiations.

"Given stock volatility often associated with market rumors, CIRO requested confirmation of a potential sale process," Bausch + Lomb stated in a December 2024 news release. "Bausch + Lomb does not intend to provide additional detail until further disclosure is appropriate or necessary."

Bausch + Lomb’s Market Position

Bausch + Lomb remains publicly traded on both the New York Stock Exchange (NYSE) and the Toronto Stock Exchange (TSX). As the company moves forward, it continues to focus on its strategic initiatives and long-term growth while maintaining transparency regarding any future developments.